(1)
JACKSON CENTER, PA / ACCESSWIRE / March 9, 2021 / Halberd Corporation s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on
The Stock Day Podcast, hosted by Everett Jolly. In the interview, Mr. Hartman reviewed the company s progress in developing SARS-CoV-2 spike protein antibodies and how they can be combined with other Halberd technologies in fighting Covid-19 and other diseases.
Hartman commented on Halberd s newly created antibody, which has been shown to have a 20 times greater affinity neutralizing than their initial antibody against the SARS-COV-2 antigen. Our efforts have been focused on developing effective antibodies against not only the spike-protein, but also against the N-protein, Hartman said. By publicizing our great progress, we might attract the interests of large company potential partners to assist in accelerating and achieving FDA approval and Emergency Use Authorization. Regardless, we plan to use our superior an
Halberd Corporation s CEO Interviewed on The Stock Day Podcast - Focus on Halberd s New 20x Affinity Neutralizing SARS-COV-2 Antibody
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Halberd Corporation s CEO Interviewed on The Stock Day Podcast - Focus on Halberd s New 20x Affinity Neutralizing SARS-COV-2 Antibody
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
CENTER VALLEY, Pa., Jan. 19, 2021 /PRNewswire/ Aesculap has been awarded a contract with Vizient that offers state-of-the-art neurosurgical technology at enhanced savings to Vizient member hospitals. The contract includes Cerebral Spinal Fluid (CSF) Management and Dural Repair and Neuro Critical Care product categories.
Vizient s diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and represents more than $100 billion in annual purchasing volume.
As a result of the award, Vizient members will now have access to contracted pricing for all of Aesculap s fixed and programmable hydrocephalus shunts, including the new